Sulodexide: Difference between revisions
m Protected "Sulodexide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 27: | Line 27: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Revision as of 16:23, 20 August 2012
| Clinical data | |
|---|---|
| Routes of administration | Oral, Subcutaneous, Intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters[1]. Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously[2].
Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury[3] and the treatment of diabetic nephropathy[4][5].
References
- ↑ Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev. 24 (3–4): 214–26. PMID 17214598.
- ↑ Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev. 18 (1): 1–20. PMID 9436179.
- ↑ Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther. 312 (2): 794–800. PMID 15365091.
- ↑ Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol. 18: 568–574. PMID 16299683.
- ↑ Gambaro G, Venturini AP, Noonan DM; et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int. 46: 797–806. PMID 7527876.
External links
- sulodexide at the US National Library of Medicine Medical Subject Headings (MeSH)
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Explicit use of et al.
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs